Loading...
Basic research and some observational studies have suggested a possible link between Chlamydia pneumoniae infection and the development of coronary heart disease (CHD). These researchers tested whether treatment with gatifloxacin, a quinolone antibiotic with activity against C. pneumoniae, might limit future cardiovascular events in patients hospitalized for an acute coronary syndrome (ACS) event in the previous 10 days. A total of 4162 such patients (mean age, 58; 78% men; 91% white) were randomized to receive placebo or gatifloxacin (400 mg daily for 2 weeks, then a 10-day course each month) as part of a 2x2 design in the multicenter, double-blind PROVE IT-TIMI 22 Trial (see Journal Watch Cardiology Feb 25 2005), cosponsored by the manufa…